AstraZeneca Pharma India: 7 Stock Signals Investors Are Watching Right Now

AstraZeneca Pharma India stock signals are unusually layered right now, with the company trading at Rs 9,091.50, the stock trades 15.0 percent below its 52 week high of Rs 10,691.00 and 37.4 percent above its 52 week low of Rs 6,619.50. AstraZeneca Pharma India is a well tracked name in the a science led pharmaceutical company focused on oncology, cardiovascular, renal, diabetes and respiratory therapy areas space, and no single headline captures where the stock stands today.

This article does not make a buy, hold or sell call on AstraZeneca Pharma India. It lays out seven signals investors commonly watch, each sourced from the company's latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.

Click Here to Get Free Investment Predictions

AstraZeneca Pharma India Stock at a Glance

Before going through each of the seven AstraZeneca Pharma India stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.

Metric	Value
AstraZeneca Pharma India CMP	Rs 9,091.50 (a recent trading session)
52-Week High	Rs 10,691.00
52-Week Low	Rs 6,619.50
Market Capitalisation	Rs 22,686 crore
P/E Ratio	113.92 (Sector P/E 39.81)
P/B Ratio	28.39
Debt to Equity	0.04
Return on Equity	28.93 percent

1. Earnings Trend at AstraZeneca Pharma India

AstraZeneca Pharma India has continued to grow through its therapy areas of Oncology, Cardiovascular, Renal and Metabolism, and Respiratory, with the company's well known products including Tagrisso, Symbicort and Farxiga contributing to steady revenue growth in recent years.

This is the first of the seven AstraZeneca Pharma India stock signals worth tracking closely into the next results.

2. FII Holding in AstraZeneca Pharma India

AstraZeneca Pharma India's FII holding stood at 2.70 percent as of 5 August 2026. DII holding stood at 0.10 percent over the same period.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

3. Promoter Holding in AstraZeneca Pharma India

Promoter holding in AstraZeneca Pharma India stood at 75.00 percent as of 5 August 2026, one of the shareholding signals worth tracking alongside institutional flows.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

4. Debt Position at AstraZeneca Pharma India

AstraZeneca Pharma India carries a debt to equity ratio of 0.04, one of the lowest among listed pharmaceutical companies, reflecting minimal reliance on external borrowing.

This is one of the balance sheet signals worth tracking alongside the earnings trend from Signal 1, since capital raising plans can shift the picture from one quarter to the next.

5. Valuation of AstraZeneca Pharma India Shares

At a P/E ratio of 113.92 against a sector average of 39.81, AstraZeneca Pharma India trades at a significant premium, reflecting its position as a multinational subsidiary with a strong innovative medicines portfolio.

Whether that valuation looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.

6. Technical Trend on the AstraZeneca Pharma India Chart

The sixth of these AstraZeneca Pharma India stock signals is the price chart itself. The stock trades 15.0 percent below its 52 week high of Rs 10,691.00 and 37.4 percent above its 52 week low of Rs 6,619.50.

Over the past year the stock has moved between Rs 6,619.50 and Rs 10,691.00, a range worth watching for a break in either direction as the next signal on where sentiment is heading.

7. Corporate Developments at AstraZeneca Pharma India

The seventh and final of these AstraZeneca Pharma India stock signals is corporate activity. AstraZeneca Pharma India, a subsidiary of AstraZeneca Pharmaceuticals AB Sweden headquartered in Bengaluru, continues to provide clinical trial services to an overseas group company alongside manufacturing, distribution and marketing of pharmaceutical products across its core therapy areas.

Check the Univest Screener for live fundamentals

What These AstraZeneca Pharma India Stock Signals Mean Together

None of these seven signals on its own settles the debate on AstraZeneca Pharma India. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.

Investors weighing AstraZeneca Pharma India would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these AstraZeneca Pharma India stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.

Conclusion

AstraZeneca Pharma India currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling AstraZeneca Pharma India shares, and readers should form their own view based on their own research and risk appetite.

Download the Univest iOS App or Univest Android App to track AstraZeneca Pharma India live price and more such signal based stock research.

FAQs on AstraZeneca Pharma India Stock Signals

Why is AstraZeneca Pharma India share price where it is right now?

Ans. AstraZeneca Pharma India shares are trading The stock trades 15.0 percent below its 52 week high of Rs 10,691.00 and 37.4 percent above its 52 week low of Rs 6,619 shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.

What is AstraZeneca Pharma India's current FII holding?

Ans. FII holding in AstraZeneca Pharma India stood at 2.70 percent as of 5 August 2026.

Is AstraZeneca Pharma India's debt position a concern right now?

Ans. AstraZeneca Pharma India carries a debt to equity ratio of 0.04, one of the lowest among listed pharmaceutical companies, reflecting minimal reliance on external borrowing.

What is the promoter holding in AstraZeneca Pharma India?

Ans. Promoter holding in AstraZeneca Pharma India stood at 75.00 percent as of 5 August 2026.

Is AstraZeneca Pharma India expensive compared to its sector?

Ans. At a P/E ratio of 113.92 against a sector average of 39.81, AstraZeneca Pharma India trades at a significant premium, reflecting its position as a multinational subsidiary with a strong innovative medicines portfolio.

What recent corporate developments are relevant to AstraZeneca Pharma India?

Ans. AstraZeneca Pharma India, a subsidiary of AstraZeneca Pharmaceuticals AB Sweden headquartered in Bengaluru, continues to provide clinical trial services to an overseas group company alongside manufacturing, distribution and marketing of pharmaceutical products across its core therapy areas.

What do the technical charts suggest about AstraZeneca Pharma India right now?

Ans. The stock trades 15.0 percent below its 52 week high of Rs 10,691.00 and 37.4 percent above its 52 week low of Rs 6,619.50.

Should investors buy AstraZeneca Pharma India shares at current levels?

Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven AstraZeneca Pharma India stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.